Clinical Trials Browser

NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Phase 1 Suspended

24 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05063565 2026-06-01

ROWAN

Phase 2 Active not recruiting

100 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Clinical Trials

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

ROWAN

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)

RADICAL

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

OMEC-5

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

SCR-ESCC-01

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Neoadjuvant Treatment Modalities in Esophageal Cancer

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study

SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer

Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases

ONTRESCC

ICC

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

iMHRT-LARC

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Local Liver Treatment for Multi-organ Colorectal Cancer Metastases

Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma

Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

AK104-IIT-13

TREE

NACSOC-02

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Miracle-1

CRATER

Thermal Ablation Followed by Immunotherapy for HCC

WATCHER

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Perioperative Therapy for Hepatocellular Carcinoma

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

RFA

ACCORD